Optosolve

Research & Development

T6030 has demonstrated a safe and efficacious analgesic effect in preclinical studies.

T6030 Mechanism of Action Pipeline Why T6030?

Introduction

What is T6030?

T6030 is a reprofiled well-known drug in a topical formulation that maintains its proven pain relief and safety, but does not have the dependency or side effect concerns of systemic formulations

Preclinical studies demonstrate that T6030 is likely metabolized at the ocular level, as the enzymes that metabolize T6030 are found in the cornea

The active ingredient of T6030 has high solubility and lipophilicity and is expected to deliver advantage in the topical formulation for application to the cornea, as only moderately charged small molecules are able to penetrate through the cornea

In preclinical studies, T6030 demonstrated that it does not impair corneal wound healing nor does it affect corneal reflex or eye blink frequency

Mechanism of Action

Treating AOP does not need to be invasive or present significant risks to the patient to be effective, and our approach with a topical analgesic gel is convenient and easy to use.
T6030 is potentially both faster-acting and safer than conventional treatment, and any treatment currently known to be in development.

T6030 is compatible with all types of contact lenses, and can be used with the Bandage Contact Lens (BCL) that is applied post-cataract surgery

T6030 blocks the Transient Receptor Potential Vanilloid-1 (TRPV1), which is an ocular pain receptor

T6030 is a preservative-free eye gel formulation with a lubricant that keeps its residence in the eye

Very small amount of the active drug is needed in the eye gel for it to be effective, potentially up to 6 hours with one dose

Pipeline

T6030 has broad potential application for AOP across numerous eye markets.

Product

Indication

Preclinical

Phase 1

Phase 2

Phase 3

T6030 is still in development and not yet approved for commercial use. The safety and efficacy of T6030 have not been demonstrated in clinical trials. There is no guarantee that T6030 will be approved and marketed in any country.

Clinical trials in ophthalmology have the second highest probability of success across all therapeutic areas, and 75% of ophthalmic trials that enter Phase 3 go on to receive NDA approval.

A pre-IND package for T6030 was submitted to the FDA who had no objections to the proposed development plan to support the initiation of Phase 2 clinical studies for the treatment of AOP.

Why T6030?

T6030 can penetrate the cornea due to its composition where it targets the ocular pain receptor directly, its ease of use allows the patient to apply it themselves, it can be used in combination with NSAIDs or steroids to treat inflammation, and is potentially fast-acting and effective.

There are no approved treatments on the market that directly address the AOP market, resulting in a substantial, global unmet medical need.
AOP is a substantial, global unmet medical need, and T6030 is the first candidate designed to treat that pain immediately
T6030 has the advantage of being formulated using a well-known drug with a well established safety and efficacy profile when administered systemically for a wide range of pain relief uses.
T6030 is fast-acting, potentially providing immediate relief, does not impair corneal wound healing and can be used in conjunction with corticosteroids and anti-imflammatories to relieve pain while allowing the eye to heal from inflamation or trauma.